Microbot Medical dries up Nasdaq listing by Investing.com’s Aktienkurses

Microbot Medical Inc. is aware of the Nasdaq, the company is active in the stock price space, but we are still active on the Nasdaq Capital Market.

From 26.08.2024 to 07.10.2024, below 1.00 US dollars, the Nasdaq Listing Rule 5550(a)(2) was changed.

Carrying out surgical and medical instruments and carrying out specialties on 07.04.2025 Time, the minimum orders for the Börsenpreis are available. It may happen that the links of the trunk maktien of the unternehmens start the first time and the subsequent trading phases are worth less than 1.00 US dollars.

Sollte Microbot Medical started on 07.04.2025 and has had one of the first 180 days to obtain the best quality of the market and other existing standards Ausnahme der Mindestpreisanforderung.

If you don’t want to spend any more money, the first thing you can do is take the Nasdaq commercial paper out of trading. Microbot Medical has the right to prevent this separation. There is no guarantee that compliance will be delayed or that there will be a warranty error.

If you start a new promotion on December 17, 2024, this will be the first time you do this. The start of the Verschiebung des Versammlungtermins is a more than 30 days in Vergleich zum Vorjahr wurde the first action for the Jahresshauptversammlung 2024 on the 25.10.2024 festgelegt. The Anträge must pronounce the SEC-Rule and the Satzung of the Unternehmens.

This information is based on the young SEC authorities of Microbot Medical Inc. and reflects the active supervisory and compliance status of the Unternehmens in the broader Nasdaq capital market.

In other cases, Microbot Medical has developed the fortress in the ACCESS-PVI study for the LIBERTY® Endovascular Robotic Surgical System, which has performed patient recruitment and 80% of the medical treatment, which has ended the treatment phase.

An investigation has been initiated with a time-long investigation and an FDA investigation through the end of 2024. Microbot Medical has completed the FDA’s final generic investigational device exemption (IDE) after all genetic biocompatibility testing has been completed.

In collaboration with Corewell Health, Microbot Medical has started the Phase-2 Development of LIBERTY-Systems for Tele-Surgery, after a phase 1.

The LIBERTY System Internal Clinical Trial investigation into Baptist Hospital of Miami has been completed, but the FDA clearance is no longer valid. External testing was performed during laboratory testing while 510(k) einreichung was being performed.

Finanziell hat Microbot Medical Sein bestehendes At-the-Market-Angebotsabkommen with HC Wainwright & Co., LLC could receive and sell a master machine with a combined prize of 4,819,905 US dollars.

If another company has a gross profit of US$2.35 million with an investment option and investment option, HC Wainwright & Co. function as an exclusive record company. HC Wainwright offered an Ausblick for Microbot Medical and paid the price of 7.00 US dollars, considering the purchase price. There are more and more studies for Microbot Medical.

InvestingPro Acknowledgment

Aktuelle InvestingPro-Daten can support the financial situation of Microbot Medical and the context of the restructuring of the Nasdaq listing. The market capitalization of the unternehmens entered a modest amount of 16.17 million US dollars and was mirrored more broadly as small-cap status. Trotz of the young benchmark of the Nasdaq-verzeichnete MBOT a one-sided price gain of 8.18%, was a kurzfristige positive Dynamik deficit.

The Unternehmen must deal with financial financing. InvestingPro-Tipps says Microbot Medical is blowing up the Barmittel and not fighting a profitable war in the last month of the month. Dies during the negative operation of -9.51 million US dollars in the last month of the second quarter of 2024. These factories can boost the volatility of the company and their camp to the shares of the Nasdaq, which spreads the brain power bones .

Positive when it comes to brands is that InvestingPro-Tipps are aware of the fact that the Unternehmen make more money as debt in the Bilanz era and their liquid assets that deliver the best sales results. This financial positioning of Microbot Medical and the flexibility of life, while it is difficult, the problem with the attention to looseness.

Investors, who analyze a number of things, can count on 9 different InvestingPro tips for MBOT successes, which will increase some of the financial prosperity and market position of our other companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.